Primary Sclerosing Cholangitis
(PSC) Treatment Research
(PSC) Treatment Research
Brigham and Women’s Hospital and Harvard Medical School are conducting a research study aimed at learning if an investigational treatment is beneficial for patients with primary sclerosing cholangitis (PSC), a disease closely related to inflammatory bowel disease (IBD). This medication is currently approved for treatment of ulcerative colitis and Crohn’s disease. Join our study and further PSC treatment research today!
Primary Sclerosing Cholangitis
(PSC) Treatment Research
(PSC) Treatment Research
Brigham and Women’s Hospital and Harvard Medical School are conducting a research study aimed at learning if an investigational treatment is beneficial for patients with primary sclerosing cholangitis (PSC), a disease closely related to inflammatory bowel disease (IBD). This medication is currently approved for treatment of ulcerative colitis and Crohn’s disease. Join our study and further PSC treatment research today!
Conducted Remotely
18 - 50
Years Old
Years Old
Fast Facts
Diagnosed with PSC & IBD
Study Background
Help researchers at Brigham and Women’s Hospital and Harvard Medical School determine if an investigational treatment benefits individuals with primary sclerosing cholangitis (PSC). Primary sclerosing cholangitis (PSC) is an inflammatory disease of the bile ducts strongly associated with inflammatory bowel disease (IBD). When individuals are diagnosed with PSC, they are at risk of developing serious complications such as progression to end-stage liver disease and multiple types of cancer. Currently, no medical treatment exists for individuals with PSC. Study participants have the opportunity to continue past the duration of the study (open-label extension/OLE). Join researchers and help find a treatment for PSC! |
Additional Information
Our goal is to determine if an investigational treatment benefits individuals with primary sclerosing cholangitis (PSC).
You may qualify to participate in this study if you meet the following criteria:
Key Criteria:
Key Criteria:
- Between the ages of 18 and 50
- Diagnosed with primary sclerosing cholangitis (PSC) & inflammatory bowel disease (IBD)
Once enrolled, this study involves:
- Virtual study visits
- Questionnaires
- Local blood draws, urine collections, and stool sample collections
- Study medicine randomization
- An opportunity to continue once the study ends (open-label extension/OLE)
Compensation is not provided for participation in this research study.
There is no cost for you to participate in our research study.